You need to create a user account to read this article.
With a subscription you unlock more content on BioStock.
Danish Vesper Bio has presented positive topline results from its Phase Ib/IIa study SORT-IN-2, where the company's lead candidate VES001 was evaluated as the first oral treatment for frontotemporal degeneration. The results show a strong increase...